NEW HAVEN, Conn. – January 5, 2016 — Melinta Therapeutics today announced that Dr. Eugene Sun, the Company’s interim Chief Executive Officer, will be providing a corporate update at the 34th annual J.P. Morgan Healthcare Conference in San Francisco, CA. Melinta’s presentation will take place on Tuesday, January 12, 2016 at 10:00am Pacific Time, and will include an update on Baxdela (delafloxacin), the Company’s lead candidate for hospital-treated skin infections and hospital-treated community-acquired bacterial pneumonia. The first of two Phase 3 studies of Baxdela (study 302) in hospital-treated skin infections met the study’s primary objective endpoint; the second Phase 3 study of IV and oral Baxdela in this indication (study 303) has completed enrollment with data expected in the first half of 2016.
The J.P. Morgan Healthcare Conference is the largest healthcare investment symposium in the industry, bringing together global industry leaders, emerging companies, technology innovators and members of the investment community. Attendance at this conference is by invitation only.
Baxdela (delafloxacin) is an investigational anionic fluoroquinolone antibiotic currently in Phase 3 clinical development for hospital-treated skin infections, known as acute bacterial skin and skin structure infections (ABSSSI). The ABSSSI PROCEED studies (studies 302 (RX-3341-302 (NCT01811732)) and 303 (RX-3341-303 (NCT01984684))) are Phase 3, multicenter, multi-national, randomized, double-blind, active-controlled trials to evaluate Baxdela compared with vancomycin + aztreonam for the treatment of patients with ABSSSI. The PROCEED studies are evaluating Baxdela in both IV and oral formulations. Baxdela has been designated a Qualified Infectious Disease Product (QIDP) for both ABSSSI and community-acquired bacterial pneumonia by the U.S. Food and Drug Administration.
About Melinta Therapeutics
Melinta Therapeutics, Inc. is dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development of novel antibiotics that provide new and better therapeutic solutions. Melinta is rapidly progressing its late-stage investigational antibiotic, Baxdela, which is currently in Phase 3 development for acute bacterial skin and skin structure infections (ABSSSI). Melinta is committed to developing, through the application of Nobel Prize-winning science, a new class of antibiotics designed to overcome the multi- and extremely-drug-resistant pathogens for which there are few to no options, known collectively as ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species and Escherichia coli), which cause the majority of life-threatening hospital infections.
Melinta Therapeutics is privately held and backed by Vatera Healthcare Partners (www.vaterahealthcare.com) and Malin Corporation plc (www.malinplc.com) among other private investors. The company is headquartered in New Haven, CT with offices in Lincolnshire, IL. Visit www.melinta.com for more information.